Skip to Navigation Skip to Search Skip to Content
Search All Centers

Updates on CAR T-Cell Therapy in Myeloma

Read Transcript Download/Print Transcript
View next

Published on June 14, 2018

The emergence of the impressive, high-tech CAR T-cell therapy, using your own genetically modified T cells to combat cancer, has generated a lot of buzz throughout the cancer community. Although it is still being evaluated in clinical trials for certain types of cancers, many multiple myeloma patients wonder if it could work for them. Where is research today on CAR T-cell therapy for myeloma? What role will this immunotherapy play in myeloma care? On location at the 2018 American Society of Clinical Oncology (ASCO) meeting in Chicago, Dr. James Berenson gives an expert perspective on the efficacy, value, toxicity and cost of CAR T-cell therapy for myeloma. Watch now to find out the latest treatment developments.


Transcript | Updates on CAR T-Cell Therapy in Myeloma

There are a number of ways it's being done.  A lot of people are targeting BCMA.  Others are targeting other protein, and, you know, there's a lot of work to be done on this in order to make it user friendly.  Right now it's pretty cumbersome.  It's really being done at major medical centers only, and there's certainly some side effects, something called cytokine release syndrome, which can be really daunting for these health staff, the nurses and ancillary healthcare professionals to take care of.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

View next